Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 15;8(10):19709-16.
eCollection 2015.

Hepatic venous pressure gradient is a useful predictor in guiding treatment on prevention of variceal rebleeding in cirrhosis

Gai-Qin Li  1 , Bo Yang  2 , Jun Liu  3 , Guang-Chuan Wang  4 , Hai-Peng Yuan  1 , Jing-Run Zhao  5 , Ji-Yong Liu  4 , Xiao-Pei Li  1 , Chun-Qing Zhang  4
Affiliations

Hepatic venous pressure gradient is a useful predictor in guiding treatment on prevention of variceal rebleeding in cirrhosis

Gai-Qin Li et al. Int J Clin Exp Med. .

Abstract

Background: The best therapy to prevent esophageal variceal (EV) rebleeding in cirrhotic patients who are non-responsive to pharmacological therapy have not been determined.

Aims: To evaluate efficacy of a strategy to assign different treatments according to hepatic vein pressure gradient (HVPG) values to prevent EV rebleeding in non-responders.

Methods: This study is a non-randomized controlled prospective study. 109 cirrhotic patients with EV bleeding who were non-responders based on two HVPG measurements were enrolled and divided two groups: 55 patients (EVL+β-blocker group) were treated with endoscopic variceal ligation (EVL) and nonselective β-blocker; 54 patients (HVPG-guided group) were treated with EVL and nonselective β-blocker if HVPG ≤ 16 mmHg (low-HVPG), with percutaneous transhepatic variceal embolization (PTVE) if HVPG > 16 mmHg and ≤ 20 mmHg (medium-HVPG), or with transjugular intrahepatic portosystemic shunt (TIPS) if HVPG > 20 mmHg (high-HVPG). Patients were followed up for rebleeding and mortality.

Results: The mean follow-up period was 17.0 months; rebleeding was higher in the EVL+β-blocker group than HVPG-guided group (25.5%, 9.3%, P = 0.026); 3-year probability of rebleeding in the EVL+Beta-blocker group increased with elevated levels of HVPG (12.5% vs 46.4% vs 64.9%, χ(2) = 11.551, P = 0.003), and 3-year probability of survival was no difference (96.6% vs 85.7% vs 90.9%, χ(2) = 2.638, P = 0.267). Rebleeding rate in PTVE group (7.7%) was lower than that in EVL+β-blockergroup with medium-HVPG (35.7%), but there was no difference. Rebleeding rate in TIPS group (7.7%) was lower than that in EVL+β-blockergroup with high-HVPG (45.5%), but there was no difference.

Conclusions: HVPG measurement was useful for making decisions to select EVL and Beta-blocker, PTVE or TIPS in secondary prophylaxis. HVPG-guided treatment is feasible and effective in preventing esophageal varices rebleeding.

Keywords: Esophageal varices bleeding; endoscopic variceal ligation; hepatic vein pressure gradient; percutaneous transhepatic variceal embolization; transjugular intrahepatic portosystemic shunt.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curves for rebleeding.
Figure 2
Figure 2
Kaplan-Meier curves for survival.
See this image and copyright information in PMC

References

    1. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762–768. - PubMed
    1. Sarin SK, Kumar A, Angus PW, Baijal SS, Baik SK, Bayraktar Y, Chawla YK, Choudhuri G, Chung JW, de Franchis R, de Silva HJ, Garg H, Garg PK, Helmy A, Hou MC, Jafri W, Jia JD, Lau GK, Li CZ, Lui HF, Maruyama H, Pandey CM, Puri AS, Rerknimitr R, Sahni P, Saraya A, Sharma BC, Sharma P, Shiha G, Sollano JD, Wu J, Xu RY, Yachha SK, Zhang C Asian Pacific Association for the Study of the Liver (APASL) Working Party on Portal Hypertension. Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations. Hepatol Int. 2011;5:607–624. - PMC - PubMed
    1. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–938. - PubMed
    1. Sharma P, Kumar A, Sharma BC, Sarin SK. Early identification of haemodynamic response to pharmacotherapy is essential for primary prophylaxis of variceal bleeding in patients with ‘high-risk’ varices. Aliment Pharmacol Ther. 2009;30:48–60. - PubMed
    1. Augustin S, Gonzalez A, Badia L, Millan L, Gelabert A, Romero A, Segarra A, Martell M, Esteban R, Guardia J, Genesca J. Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding. Hepatology. 2012;56:706–714. - PubMed

LinkOut - more resources